loading page

MMP-2 regulates Src activation via repression of the CHK/MATK tumor suppressor in Osteosarcoma
  • +1
  • Deanna Maybee,
  • Christopher Cromwell,
  • Basil Hubbard,
  • Mohammad Ali
Deanna Maybee
Binghamton University School of Pharmacy and Pharmaceutical Sciences
Author Profile
Christopher Cromwell
University of Toronto
Author Profile
Basil Hubbard
University of Toronto
Author Profile
Mohammad Ali
Binghamton University School of Pharmacy and Pharmaceutical Sciences

Corresponding Author:[email protected]

Author Profile


Doxorubicin, a first-line anticancer drug for osteosarcoma treatment, has been the subject of recent research exploring the mechanisms behind its chemoresistance and its ability to enhance cell migration at sublethal concentrations. Matrix metalloproteinase-2 (MMP-2), a type IV collagenase and zinc-dependent endopeptidase, is well-known for degrading the extracellular matrix and promoting cancer metastasis. Our previous work demonstrated that nuclear MMP-2 regulates ribosomal RNA transcription via histone clipping, thereby controlling gene expression. Additionally, MMP-2 activity is regulated by the non-receptor tyrosine kinase and oncogene, Src, which plays a crucial role in cell adhesion, invasion, and metastasis. Src kinase is primarily regulated by two endogenous inhibitors: C-terminal Src kinase (Csk) and Csk homologous kinase (CHK/MATK). In this study, we reveal that the MMP-2 gene acts as an upstream regulator of Src kinase activity by suppressing its endogenous inhibitor, CHK/MATK, in osteosarcoma cells. We also show that enhanced osteosarcoma cell migration which is induced by sublethal concentrations of doxorubicin can be overcome by inactivating the MMP-2 gene or overexpressing CHK/MATK. Our findings highlight the MMP-2 gene as a promising additional target for combating cancer cell migration and metastasis. This is due to its impact on the gene and protein expression of the tumor suppressor CHK/MATK in osteosarcoma. By targeting the MMP-2 gene, we can potentially enhance the effectiveness of doxorubicin treatment and reduce chemoresistance in osteosarcoma.
06 Jun 2023Submitted to Cancer Reports
08 Jun 2023Submission Checks Completed
08 Jun 2023Assigned to Editor
08 Jun 2023Review(s) Completed, Editorial Evaluation Pending
12 Jun 2023Reviewer(s) Assigned
28 Jun 2023Editorial Decision: Revise Major
22 Aug 20231st Revision Received
23 Aug 2023Submission Checks Completed
23 Aug 2023Assigned to Editor
23 Aug 2023Review(s) Completed, Editorial Evaluation Pending
24 Aug 2023Reviewer(s) Assigned
14 Sep 2023Editorial Decision: Accept